Here, we discuss the effect of omalizumab in malignant idiopathic anaphylaxis in light of recent literature by presenting our treatment experience in a patient with steroid-dependent malignant idiopathic anaphylaxis.
With these clinical and laboratory findings, a diagnosis of idiopathic anaphylaxis was made, because no relationship with any known triggering factor could definitively be demonstrated.
The patient was thought to have steroid-dependent malignant idiopathic anaphylaxis because the prednisolone dose could not be reduced below 30 mg daily.
A 74-year-old man was referred for evaluation of recurrent urticaria and idiopathic anaphylaxis, which he reported he had had since 1963.
There is also a group of patients, such as the patient in this report, who have idiopathic anaphylaxis in whom an antigen or precipitating factor is not identified.